http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-108938584-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2018 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-205 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4709 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2021-01-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-108938584-B |
| titleOfInvention | Tablet containing VEGF receptor inhibitor Tivozanib salt and preparation method thereof |
| abstract | The invention discloses a tablet containing a VEGF receptor inhibitor Tivozanib salt, which consists of a pharmaceutical active ingredient and an auxiliary material, wherein the pharmaceutical active ingredient is N- { 2-chloro-4- [ (6, 7-dimethoxy-4-quinolyl) oxy ] phenyl } -N' - (5-methyl-3-isoxazolyl) urea (Tivozanib); the auxiliary materials comprise a filling agent, an adhesive, a disintegrating agent and a lubricant, and simultaneously contain lactose and beta-cyclodextrin. The tablet containing the VEGF receptor inhibitor Tivozanib salt is prepared by mixing Tivozanib and beta-cyclodextrin, grinding the mixture to micropowder, adding lactose into the micropowder, continuously grinding the micropowder, adding other auxiliary materials, and tabletting. |
| priorityDate | 2018-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 107.